INVO Bioscience, Inc. (INVO)
NASDAQ: INVO · IEX Real-Time Price · USD
0.741
-0.006 (-0.87%)
Jul 22, 2024, 9:56 AM EDT - Market open
INVO Bioscience Employees
As of December 31, 2023, INVO Bioscience had 30 total employees, including 25 full-time and 5 part-time employees. The number of employees increased by 14 or 87.50% compared to the previous year.
Employees
30
Change (1Y)
14
Growth (1Y)
87.50%
Revenue / Employee
$141,628
Profits / Employee
-$236,008
Market Cap
2.86M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Aditxt | 47 |
TC Biopharm (Holdings) | 41 |
ASLAN Pharmaceuticals | 35 |
Petros Pharmaceuticals | 21 |
Virax Biolabs Group | 11 |
Altamira Therapeutics | 10 |
Alzamend Neuro | 7 |
CNS Pharmaceuticals | 5 |
INVO News
- 2 months ago - INVO Reports Record First Quarter 2024 Financial Results - GlobeNewsWire
- 3 months ago - INVO Reports Fourth Quarter and Full Year 2023 Financial Results - GlobeNewsWire
- 8 months ago - NAYA Biosciences Announces Publication of New Data for its CD38-targeted Flex-NK™ Bispecific Antibody in the American Society of Hematology's Blood Journal - PRNewsWire
- 8 months ago - NAYA Biosciences and ONK Therapeutics Announce Research Partnership to Advance Combination Therapy of FLEX-NK™ Bispecific Antibodies and Optimally Engineered Off-the-Shelf Natural Killer Cell Therapies - PRNewsWire
- 8 months ago - INVO Bioscience Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement - PRNewsWire
- 8 months ago - INVO Reports Record Third Quarter 2023 Financial Results - PRNewsWire
- 9 months ago - NAYA Biosciences and INVO Bioscience Announce Appointment of Dr. Peter Kash, Ed.D., MBA as Vice Chairman Following Closing of Their Pending Merger - PRNewsWire
- 9 months ago - INVO Bioscience Announces Commencement of Waiver Solicitation From Holders of the Company's Common Stock Purchase Warrants - PRNewsWire